As of April 2024 Intra-Cellular Therapies has a market cap of $7.47 Billion. This makes Intra-Cellular Therapies the world's 1960th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $7.47 B | 8.46% |
2023 | $6.89 B | 37.53% |
2022 | $5.01 B | 17.54% |
2021 | $4.26 B | 66.64% |
2020 | $2.55 B | 34.35% |
2019 | $1.90 B | 204.59% |
2018 | $0.62 B | -20.88% |
2017 | $0.79 B | 21.04% |
2016 | $0.65 B | -71.87% |
2015 | $2.32 B | 345.85% |
2014 | $0.52 B | 17.48% |
2013 | $0.44 B |
On Apr 17th, 2024 the market cap of Intra-Cellular Therapies was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Xencor XNCR | $1.16 B | -84.41% | ๐บ๐ธ USA |
MediciNova MNOV | $70.13 M | -99.06% | ๐บ๐ธ USA |
Curis CRIS | $94.01 M | -98.74% | ๐บ๐ธ USA |